Anticarin-beta shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair proteostasis
文献类型：期刊论文
| 作者 | Wang, Gan; Zhang, Min; Meng, Ping; Long, Chengbo; Luo, Xiaodong ; Yang, Xingwei; Wang, Yunfei; Zhang, Zhiye; Mwangi, James; Kamau, Peter Muiruri
|
| 刊名 | ACTA PHARMACEUTICA SINICA B
 |
| 出版日期 | 2022 |
| 卷号 | 12期号:5页码:2268-2279 |
| 关键词 | Proteostasis CCT TRiC Osteosarcoma STAT3 Anticarin-beta PDX model CYTOSOLIC CHAPERONIN CANCER-CELLS COMPLEX EXPRESSION SURVIVAL PROTEIN TUBULIN GROWTH |
| DOI | 10.1016/j.apsb.2021.12.024 |
| 英文摘要 | Unlike healthy, non-transformed cells, the proteostasis network of cancer cells is taxed to produce proteins involved in tumor development. Cancer cells have a higher dependency on molecular chaperones to maintain proteostasis. The chaperonin T-complex protein ring complex (TRiC) contains eight paralogous subunits (CCT1-8), and assists the folding of as many as 10% of cytosolic proteome. TRiC is essential for the progression of some cancers, but the roles of TRiC subunits in osteosarcoma remain to be explored. Here, we show that CCT4/TRiC is significantly correlated in human osteosarcoma, and plays a critical role in osteosarcoma cell survival. We identify a compound anticarin-beta that can specifically bind to and inhibit CCT4. Anticarin-beta shows higher selectivity in cancer cells than in normal cells. Mechanistically, anticarin-beta potently impedes CCT4-mediated STAT3 maturation. Anticarin-beta displays remarkable antitumor efficacy in orthotopic and patient-derived xenograft models of osteosarcoma. Collectively, our data uncover a key role of CCT4 in osteosarcoma, and propose a promising treatment strategy for osteosarcoma by disrupting CCT4 and proteostasis. (C) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. |
| WOS记录号 | WOS:000810889400009 |
| 源URL | [http://ir.kib.ac.cn/handle/151853/74772]  |
| 专题 | 中国科学院昆明植物研究所 |
| 推荐引用方式 GB/T 7714 | Wang, Gan,Zhang, Min,Meng, Ping,et al. Anticarin-beta shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair proteostasis[J]. ACTA PHARMACEUTICA SINICA B,2022,12(5):2268-2279. |
| APA | Wang, Gan.,Zhang, Min.,Meng, Ping.,Long, Chengbo.,Luo, Xiaodong.,...&Lai, Ren.(2022).Anticarin-beta shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair proteostasis.ACTA PHARMACEUTICA SINICA B,12(5),2268-2279. |
| MLA | Wang, Gan,et al."Anticarin-beta shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair proteostasis".ACTA PHARMACEUTICA SINICA B 12.5(2022):2268-2279. |
入库方式： OAI收割
来源：昆明植物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。